CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts

Price target

1,614.590.000.00%
The 25 analysts offering 1 year price forecasts for CRSP/N have a max estimate of — and a min estimate of —.

Analyst rating

Based on 31 analysts giving stock ratings to CRSP/N in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


CRSP/N EPS for the last quarter is −19.90 MXN despite the estimation of −27.28 MXN. In the next quarter EPS is expected to reach −28.07 MXN. Track more of CRISPR THERAPEUTICS AG financials and stay on top of what is up with the company.
In the next quarter CRISPR THERAPEUTICS AG revenue is expected to reach ‪130.93 M‬ MXN. Check out CRISPR THERAPEUTICS AG revenue and earnings and make informed decisions.
According to analysts, CRSP/N price target is 1,614.59 MXN with a max estimate of 4,005.64 MXN and a min estimate of 603.86 MXN. Check if this forecast comes true in a year, meanwhile watch CRISPR THERAPEUTICS AG stock price chart and keep track of the current situation with CRSP/N news and stock market news.
We've gathered opinions of 31 analysts rating CRSP/N stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.